Review article
Involvement of circulating inflammatory factors in prognosis and risk of cardiovascular disease

https://doi.org/10.1016/j.yjmcc.2019.05.010Get rights and content

Highlights

  • Upregulation of inflammatory factors is involved in endothelial dysfunction in CVD.

  • There is a link between inflammatory factors and severity of thrombosis in CVD.

  • The dietary patterns could be related to clinical and biological features of CVD risk.

  • Circulating inflammatory factors can be regarded as potential prognostic biomarkers for clinical outcome of CVD.

Abstract

Cardiovascular disease (CVD) is an inflammatory disease that different factors play a crucial role in the development of clinical outcome of this disease. Inflammation could have effects on initiation, progression, and clinical complications of CVD. Previous studies have indicated that delineating the underlying mechanisms of inflammatory factors involved in this disease should be considerably beneficial both as predictive markers and targets for advancement of appropriate therapeutic approaches in offsetting development and progression of cardiovascular complications. Mechanisms of inflammatory factors involved in CVD combined with the development of atherosclerosis, reperfusion injury, and myocardial infarction caused by changes in processes such as endothelial cells function and hemostasis can contribute to the development of clinical outcome in CVD. Therefore, it can be stated that recognition of inflammatory mechanisms involved in this disease can be a promising tool for evaluation of prognosis in CVD patients. In this article, our goal is to evaluate the possible role of changes in the expressions of inflammatory factors in CVD as well as their relationship with prognosis of this disease.

Introduction

Inflammation is a protective response aligned with the release of inflammatory factors from immune cells against pathogens, which is associated with tissue damage [1,2]. As pathological processes, inflammatory pathways are effective in the initiation and progression of disease [1], whereby inflammatory factors can act as peripheral clinical markers for vascular wall inflammation [3]. Furthermore, imbalance in the immune response via increase in the damage of myocardium can trigger initiation, progression, and eventual complications of atherosclerosis [1,4,5]. Atherosclerosis results from an increase in inflammatory factors such as acute phase proteins and cytokines, and subsequent changes in endothelium of coronary arteries, and can act as a risk factor for cardiovascular disease (CVD) [6]. CVD is a widespread cause of mortality in which various contributors entailing elevated cholesterol levels, insulin resistance, diabetes, obesity, and inflammatory diseases are involved as risk factors through developing atherosclerotic lesions [4]. Biologic activities of inflammatory factors in CVD can be effective in plaque formation and rupture, endothelial dysfunction, and eventually coronary thrombosis [7]. Regarding the link between atherosclerosis factors with its stages, it seems that inflammatory factors may directly increase the risk of CVD and myocardial infarction (MI) or stroke. Given the significant role of inflammatory processes in CVD pathophysiology, we aimed to assess changes in the expression of inflammatory factors in CVD, and, secondarily, the possibility of their role as prognostic factors in this disease.

Section snippets

Mechanisms of inflammation in CVD

Production of inflammatory cytokines and acute phase proteins following immune response in CVD patients can act as a biochemical risk factor in atherosclerosis development [4]. Since atherosclerosis plays an important role in CVD pathological process [3], knowledge of mechanisms and biological activities of inflammatory factors such as interleukin 6 (IL-6), C-reactive protein (CRP), fibrinogen, tumor necrosis factor alpha (TNF-α), and glycoprotein acetylation (GlycA) that are involved in

Association between inflammatory factors and endothelial dysfunction

ECs forming internal lumen of the vasculature are major players in controlling vascular tone such as regulating vasodilation and vasoconstriction, growth of vascular smooth muscle cells, inflammation, hemostasis, and maintaining a proper blood supply to tissues [2,76]. ECs dysfunction is a leading cause of vascular diseases such as atherosclerosis and CVD [2], and inflammation is one of causal factors in ECs damages that can trigger ECs dysfunction [2,76]. As a major factor of inflammation,

Role of inflammatory factors in thrombosis

As a major component of homeostasis, platelets have a crucial role in thrombosis via secretion of factors including inflammatory cytokines, platelet-derived growth factors, and thrombin [97]. Since thrombosis takes place after activation of immune system and inflammation, it has been observed that platelets contribute to the induction of inflammation through interaction with leukocytes as well as their trafficking and migration towards the atherosclerotic plaque, which have significant effects

Inflammatory genes polymorphisms and their effects on CVD

Inflammatory system and cytokines involved in it have essential roles in the development of CVD. Gene polymorphisms of these cytokines through changes in their expressions can serve as risk factors in CVD [111]. Presence of −174 G>C polymorphism in IL-6 gene increases the risk of developing MI via overexpression of IL-6 in CC genotype and elderly compared to younger individuals and GG genotype [112,113]. Other studies have also shown the upregulation of CRP in 2174C allele compared to 2174G

Evaluating the effects of dietary pattern on the risk of CVD

CVD is highly affected by lifestyle, including dietary pattern, smoking, and physical activity [136], so that diet through modulation of inflammation could have an important role in the development of cardiovascular events [137]. The effect of diet on CVD depends on pro- or anti-inflammatory power composition of the diet [138]. It has been reported that dietary patterns high in refined starches, sugar, and lipids and poor in natural antioxidants and fiber could have role in creating an

Discussion

Inflammation is one of the key contributing factors in CVD, where interactions between immune cells, vascular cells, and release of inflammatory factors appear to modulate pathogenesis of disease in this process. Previous studies have indicated that delineating the underlying mechanisms of inflammatory mediators and acute phase proteins involved in this disease should be considerably beneficial both as predictive markers and targets for advancement of appropriate therapeutic approaches in

Conclusion

Given the role of inflammation in initiation, progression, and clinical complications of CVD, in this review article, this hypothesis has been proposed that the expression rates of inflammatory mediators in CVD have prognostic value. Overall, knowledge of the prognostic value of inflammatory mediators is helpful in anticipating clinical course of this disease along with the hope of improving appropriate and timely therapeutic interventions that could substantially ameliorate problems associated

Acknowledgement

We wish to thank all our colleagues in Shafa Hospital and Allied Health Sciences School, Ahvaz Jundishapur University of Medical Sciences.

Authors' contributions

N.S. conceived the manuscript and revised it; H.H., M.Sh., M.B., N.D. wrote the manuscript and prepared the Table and figure.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Conflict of interest

The authors declare no conflict of interest.

References (145)

  • J.-J. Li et al.

    C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases

    Med. Hypotheses

    (2004)
  • M.A. Maturana

    Relationship between endogenous testosterone and cardiovascular risk in early postmenopausal women

    Metab. Clin. Exp.

    (2008)
  • R. Tian

    C-reactive protein for predicting cardiovascular and all-cause mortality in type 2 diabetic patients: a meta-analysis

    Cytokine

    (2019)
  • N.J. Pagidipati

    High-sensitivity C-reactive protein elevation in patients with prior myocardial infarction in the United States

    Am. Heart J.

    (2018)
  • M.Z. Diederichsen

    Prognostic value of suPAR and hs-CRP on cardiovascular disease

    Atherosclerosis

    (2018)
  • Y. Pokharel

    High-sensitivity C-reactive protein levels and health status outcomes after myocardial infarction

    Atherosclerosis

    (2017)
  • D. Tousoulis

    Fibrinogen and cardiovascular disease: genetics and biomarkers

    Blood Rev.

    (2011)
  • G. Ndrepepa

    Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease

    Am. J. Cardiol.

    (2013)
  • M.N. Sack

    Tumor necrosis factor-α in cardiovascular biology and the potential role for anti-tumor necrosis factor-α therapy in heart disease

    Pharmacol. Ther.

    (2002)
  • A.M. Feldman

    The role of tumor necrosis factor in the pathophysiology of heart failure

    J. Am. Coll. Cardiol.

    (2000)
  • A.C. Carlsson

    Levels of soluble tumor necrosis factor receptor 1 and 2, gender, and risk of myocardial infarction in northern Sweden

    Atherosclerosis

    (2018)
  • S.C. Ritchie

    The biomarker GlycA is associated with chronic inflammation and predicts long-term risk of severe infection

    Cell Syst.

    (2015)
  • A. Ezeigwe

    The novel inflammatory marker GlycA and the prevalence and progression of valvular and thoracic aortic calcification: the multi-ethnic study of atherosclerosis

    Atherosclerosis

    (2019)
  • J.B. Muhlestein

    GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: the intermountain heart collaborative study

    Am. Heart J.

    (2018)
  • E.G. Gruppen

    Higher plasma GlycA, a novel pro-inflammatory glycoprotein biomarker, is associated with reduced life expectancy: the PREVEND study

    Clin. Chim. Acta

    (2019)
  • M. Romano

    Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment

    Immunity

    (1997)
  • P.A. Fordjour

    Possible mechanisms of C-reactive protein mediated acute myocardial infarction

    Eur. J. Pharmacol.

    (2015)
  • H. Nishida

    Interleukin-6 as an independent predictor of future cardiovascular events in high-risk Japanese patients: comparison with C-reactive protein

    Cytokine

    (2011)
  • J. Walter

    Clinical utility of circulating interleukin-6 concentrations in the detection of functionally relevant coronary artery disease

    Int. J. Cardiol.

    (2019)
  • H.E. Groot

    Soluble interleukin 6 receptor levels are associated with reduced myocardial reperfusion after percutaneous coronary intervention for acute myocardial infarction

    Cytokine

    (2015)
  • C.M. Ferrario et al.

    Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease

    Am. J. Cardiol.

    (2006)
  • C. Han

    Angiotensin II induces C-reactive protein expression through ERK1/2 and JNK signaling in human aortic endothelial cells

    Atherosclerosis

    (2010)
  • N.C. Riedemann et al.

    Complement in ischemia reperfusion injury

    Am. J. Pathol.

    (2003)
  • E.M. Golebiewska et al.

    Platelet secretion: from haemostasis to wound healing and beyond

    Blood Rev.

    (2015)
  • W. Fu

    Myocardial infarction induces bone marrow megakaryocyte proliferation, maturation and platelet production

    Biochem. Biophys. Res. Commun.

    (2019)
  • E.T. Askevold

    Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure

    Curr. Heart Fail. Rep.

    (2014)
  • C. Zhang

    The role of inflammatory cytokines in endothelial dysfunction

    Basic Res. Cardiol.

    (2008)
  • F. Davis

    C-reactive protein and coronary heart disease-risk marker or risk factor

    J. Clin. Sci. Res.

    (2012)
  • M.Y. Abeywardena

    Cardiovascular biology of interleukin-6

    Curr. Pharm. Des.

    (2009)
  • B. Zhang

    Interleukin-6 as a predictor of the risk of cardiovascular disease: a meta-analysis of prospective epidemiological studies

    Immunol. Investig.

    (2018)
  • G.K. Hansson

    Inflammation, atherosclerosis, and coronary artery disease

    N. Engl. J. Med.

    (2005)
  • T. Kanda et al.

    Interleukin-6 and cardiovascular diseases

    Jpn. Heart J.

    (2004)
  • D. Qu

    IL-6 in diabetes and cardiovascular complications

    Br. J. Pharmacol.

    (2014)
  • M.L. Morieri

    Interleukin-6 “trans-signaling” and ischemic vascular disease: the important role of soluble gp130

    Mediat. Inflamm.

    (2017)
  • I.M. Velásquez

    Circulating levels of interleukin 6 soluble receptor and its natural antagonist, sgp130, and the risk of myocardial infarction

    Atherosclerosis

    (2015)
  • J. Danesh

    Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review

    PLoS Med.

    (2008)
  • N. Sattar

    Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events?

    PLoS Med.

    (2009)
  • C. Held

    Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (stabilization of atherosclerotic plaque by initiation of Darapladib therapy) trial

    J. Am. Heart Assoc.

    (2017)
  • M. Cesari

    Inflammatory markers and onset of cardiovascular events: results from the health ABC study

    Circulation

    (2003)
  • D. Fujita

    Circulating interleukin-6 (IL-6) levels are associated with aortic dimensions in genetic aortic conditions

    PLoS One

    (2019)
  • Cited by (27)

    • Cardiometabolic risk, biomarkers of low-grade subclinical inflammation and flavonoid intake: A cross-sectional study in Argentina

      2022, PharmaNutrition
      Citation Excerpt :

      Cardiometabolic Diseases (CMDs), including cardiovascular diseases, diabetes mellitus and obesity, are responsible for about 60% of the total deaths caused by NCDs [1]. In these pathologies, different risk factors such as smoking habit, sedentary lifestyle, alcohol abuse, unbalanced diet and metabolic oxidative stress play a central role in the development of proinflammatory status [3,4]. Inflammation is a natural response induced by cell injury and its consequences.

    • Dyslipidemia influences the effect of physical exercise on inflammatory markers on obese women in post-menopause: A randomized clinical trial

      2021, Experimental Gerontology
      Citation Excerpt :

      However, people with diabetes are at increased risk of dyslipidemia (Gazzaz et al., 2020), associated with increased concentrations of inflammatory markers and vascular and cardiac changes (Kozakova et al., 2019). Thus, both diabetes (Karan et al., 2020) and dyslipidemia are related to increased endothelial dysfunction (Fan et al., 2018), which, in turn, contributes to greater expression of inflammatory factors (Haybar et al., 2019). In our study, a higher proportion of women with diabetes was observed in the groups with dyslipidemia, mainly in CGD, however in the EGD group, a significant reduction in TNF-α values was observed, even with a greater proportion of patients with diabetes, but without effect a significant increase in IL-6 values.

    View all citing articles on Scopus
    View full text